Cargando…

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors

The NRAS and BRAF genes are frequently mutated in melanoma, suggesting that the NRAS-BRAF-MEK-ERK signaling pathway is an important target for therapy. Two classes of drugs, one targeting activated BRAF and one targeting MEK, are currently undergoing clinical evaluation. We have analysed the NRAS an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stones, Clare J., Kim, Ji Eun, Joseph, Wayne R., Leung, Euphemia, Marshall, Elaine S., Finlay, Graeme J., Shelling, Andrew N., Baguley, Bruce C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647113/ https://www.ncbi.nlm.nih.gov/pubmed/23658559 http://dx.doi.org/10.3389/fgene.2013.00066

Ejemplares similares

Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines
por: Kim, Ji Eun, et al.
Publicado: (2012)

Heterogeneity of expression of epithelial–mesenchymal transition markers in melanocytes and melanoma cell lines
por: Kim, Ji Eun, et al.
Publicado: (2013)

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
por: Sweetlove, Melanie, et al.
Publicado: (2015)

The Role of the Hippo Pathway in Melanocytes and Melanoma
por: Kim, Ji Eun, et al.
Publicado: (2013)

Derivation of Breast Cancer Cell Lines Under Physiological (5%) Oxygen Concentrations
por: Leung, Euphemia Y., et al.
Publicado: (2018)

Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers
por: Leung, Euphemia Y., et al.
Publicado: (2017)

Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines
por: Leung, Euphemia Y., et al.
Publicado: (2015)

Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma
por: Hui, Caressa, et al.
Publicado: (2022)

Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanoma
por: Homan, Morgan, et al.
Publicado: (2022)

Epigenetic regulation in human melanoma: past and future
por: Sarkar, Debina, et al.
Publicado: (2015)

Relationships between Signaling Pathway Usage and Sensitivity to a Pathway Inhibitor: Examination of Trametinib Responses in Cultured Breast Cancer Lines
por: Leung, Euphemia Y., et al.
Publicado: (2014)

Hormone Resistance in Two MCF-7 Breast Cancer Cell Lines is Associated with Reduced mTOR Signaling, Decreased Glycolysis, and Increased Sensitivity to Cytotoxic Drugs
por: Leung, Euphemia Yee, et al.
Publicado: (2014)

Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?
por: Stagno, Anna, et al.
Publicado: (2021)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Evidence That GRIN2A Mutations in Melanoma Correlate with Decreased Survival
por: D’mello, Stacey Ann N., et al.
Publicado: (2014)

Multiple Isoforms of ANRIL in Melanoma Cells: Structural Complexity Suggests Variations in Processing
por: Sarkar, Debina, et al.
Publicado: (2017)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

Evidence for the Existence of Triple-Negative Variants in the MCF-7 Breast Cancer Cell Population
por: Leung, Euphemia, et al.
Publicado: (2014)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
por: Hamid, Omid, et al.
Publicado: (2019)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021)

Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
por: Ryu, Sunhyo, et al.
Publicado: (2017)

A Predictive Model of Adaptive Resistance to BRAF/MEK Inhibitors in Melanoma
por: Ruiz, Emmanuelle M., et al.
Publicado: (2023)

Correction: Sarkar, D., et al. Multiple Isoforms of ANRIL in Melanoma Cells: Structural Complexity Suggests Variations in Processing. Int. J. Mol. Sci. 2017, 18, 1378
por: Sarkar, Debina, et al.
Publicado: (2018)

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors
por: Ismail, Rawa K., et al.
Publicado: (2022)

Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III–IV Melanoma: A Systematic Review and Meta-Analysis
por: Liu, Ye, et al.
Publicado: (2021)

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
por: Booth, Andrew E. C., et al.
Publicado: (2020)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
por: Gouda, M.A., et al.
Publicado: (2023)

Case report: Clinical success targeting BRAF-mutated, hormone receptor positive, HER2- negative advanced breast cancer patient with BRAF-inhibitor plus MEK- inhibitor
por: López de Sá, Alfonso, et al.
Publicado: (2022)

Case Report: Delayed Onset Multi-Organ Toxicities in a Melanoma Patient Achieving Complete Response to BRAF/MEK Inhibition
por: Knochelmann, Hannah M., et al.
Publicado: (2022)

Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma
por: Maeda, Takuya, et al.
Publicado: (2023)

Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK
por: Tran, Khanh B., et al.
Publicado: (2021)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
por: Reinhard, Raphael, et al.
Publicado: (2018)

Phosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma
por: Parker, Robert, et al.
Publicado: (2015)

Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma
por: Lau, Peter Kar Han, et al.
Publicado: (2021)

Keeping abreast with long non-coding RNAs in mammary gland development and breast cancer
por: Hansji, Herah, et al.
Publicado: (2014)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
por: Ascierto, Paolo A., et al.
Publicado: (2023)

Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib
por: Gavric, Ana Ursula, et al.
Publicado: (2018)

Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model
por: Lai, Xiulan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_j6f8u4ompdmi1lkhf5fblicjfd